Lumicell’s Cancer Imaging Drug Faces Clinical Meaningfulness, Anaphylaxis Risk Questions At FDA Panel

US FDA advisory committee briefing documents say drug-device combo Lumisight (pegulicianine) is effective at picking up cancer but it is not clear whether that translates to patient benefit.

two people in operating room performing surgery
Lumicell hopes to help breast cancer patients avoid a second surgery with its medical imaging drug. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers